<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665596</url>
  </required_header>
  <id_info>
    <org_study_id>CW19-01RS</org_study_id>
    <nct_id>NCT04665596</nct_id>
  </id_info>
  <brief_title>Valvosoft First-In-Human Study in Severe Symptomatic Aortic Stenosis</brief_title>
  <official_title>Prospective, Controlled, Single-arm Clinical Investigation for the Treatment of Subjects With Severe Symptomatic Aortic Valve Stenosis Using Valvosoft® Pulsed Cavitational Ultrasound Therapy (PCUT) - First-In-Human</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiawave SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiawave SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, controlled, single-arm clinical investigation for the treatment of&#xD;
      subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational&#xD;
      Ultrasound Therapy (PCUT) - First-In-Human&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CARDIAWAVE has developed a new non-invasive, real-time image-guided, therapeutic approach to&#xD;
      treat patients suffering from Calcified Aortic Stenosis. CARDIAWAVE's Valvosoft device is a&#xD;
      new ultrasound therapy based on a disruptive technology involving delivering an extremely&#xD;
      precise and focused ultrasound beam to perform a reparative effect on the aortic valve&#xD;
      leaflets, softening the valve's tissues, restoring leaflet mobility, and therefore improving&#xD;
      the overall clinical status related to the aortic valve stenosis. In this study, a brai-MRI&#xD;
      is performed before the procedure and 24-72 hours after the procedure to detect&#xD;
      cerebrovascular events.This is a FIM study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">February 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ultrasound treatment of calcific aortic stenosis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Rate of procedure related mortality</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Rate of procedure related mortality at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device performance to modify valve structure as measured by echocardiography</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Ability to modify the Aortic Valve Area (mm2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device performance to modify valve structure as measured by echocardiography</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Ability to modify the Left Ventricular Ejection Fraction (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device performance to modify valve structure as measured by echocardiography</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Ability to modify the Mean Pressure Gradient (mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to two years</time_frame>
    <description>Number of patients that die during the course of the study and if so, how long aftre the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke</measure>
    <time_frame>Up to two years</time_frame>
    <description>Rate of stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of severity of heart failure</measure>
    <time_frame>At 1,3,6,12 and 24 months</time_frame>
    <description>Change of New York Heart Association class (I-IV - stage of severity of heart failure - I=no symptoms, IV= symptoms at rest)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Rate of Major Adverse Events (MAE) and number of patients with one or more MAE during the course of the study, an MAE defined as: Disabling stroke, Myocardial infarction or any clinically significant changes in biomarkers (CK, Troponin I - T) that would indicate damage to the heart structure, or clinically significant conduction disturbances requiring pacemaker implantation or persistent arrhythmias</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Ultrasound treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound treatment</intervention_name>
    <description>Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen</description>
    <arm_group_label>Ultrasound treatment</arm_group_label>
    <other_name>Ultrasound treatment of calcific aortic valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects suffering from severe symptomatic aortic valve stenosis according to ESC 2017&#xD;
             definition, including subjects with a bicuspid valve.&#xD;
&#xD;
          -  Patient is not eligible for TAVR/SAVR according to local Heart Team.&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  Subjects who are willing to provide a written informed consent prior to participating&#xD;
             in the study.&#xD;
&#xD;
          -  Subjects who can comply with the study follow up or other study requirements.&#xD;
&#xD;
          -  Patient is eligible for the Valvosoft procedure according to CRC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any electrical device implanted.&#xD;
&#xD;
          -  Subjects with unstable arrhythmia not controlled by medical treatment.&#xD;
&#xD;
          -  Subjects with implanted mechanical valve in any position or bio prosthetic valve in&#xD;
             aortic position.&#xD;
&#xD;
          -  Subjects with complex congenital heart disease.&#xD;
&#xD;
          -  Chest deformity.&#xD;
&#xD;
          -  Cardiogenic shock.&#xD;
&#xD;
          -  History of heart transplant.&#xD;
&#xD;
          -  Subjects requiring other cardiac surgery procedures (bypass graft surgery, mitral&#xD;
             valve procedure, tricuspid valve procedure) within one month after treatment.&#xD;
&#xD;
          -  Thrombus in heart.&#xD;
&#xD;
          -  Acute myocardial infarction (MI), stroke or transient ischemic attack (TIA) within one&#xD;
             month prior to enrolment*.&#xD;
&#xD;
          -  Subjects who are pregnant or nursing.&#xD;
&#xD;
          -  Subjects who are participating in another research study for which the primary&#xD;
             endpoint has not been reached.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Messas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Georges Pompidou, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk Pauwels</last_name>
    <phone>+32475845836</phone>
    <email>dirk.pauwels@cardiawave.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Centre of Serbia</name>
      <address>
        <city>Belgrad</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radmila Karan, MD</last_name>
      <phone>+381638873209</phone>
      <email>rkaran@md-clinicals.com</email>
    </contact>
    <investigator>
      <last_name>Danijela Trifunovic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milos Velinovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>symptomatic</keyword>
  <keyword>aortic valve</keyword>
  <keyword>stenosis</keyword>
  <keyword>ultrasound</keyword>
  <keyword>non-invasive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

